12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Company News  |  Other News

Merck & Co., Institute for Research in Immunology and Cancer-Commercialization of Research (IRICoR) cancer, autoimmune news

Merck will provide C$4 million ($3.9 million) in funding to IRICoR to identify, develop and commercialize healthcare technologies in collaboration with MaRs Innovation (Toronto, Ontario) and the Centre for Drug Research and Development (Vancouver, B.C.). IRICoR is a not-for-profit dedicated to commercializing cancer,...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >